0001209191-18-054840.txt : 20181011
0001209191-18-054840.hdr.sgml : 20181011
20181011195903
ACCESSION NUMBER: 0001209191-18-054840
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181009
FILED AS OF DATE: 20181011
DATE AS OF CHANGE: 20181011
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shak Steven
CENTRAL INDEX KEY: 0001337334
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51541
FILM NUMBER: 181119166
MAIL ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GENOMIC HEALTH INC
CENTRAL INDEX KEY: 0001131324
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 770552594
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
BUSINESS PHONE: 650-556-9300
MAIL ADDRESS:
STREET 1: 301 PENOBSCOT DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-10-09
0
0001131324
GENOMIC HEALTH INC
GHDX
0001337334
Shak Steven
301 PENOBSCOT DRIVE
REDWOOD CITY
CA
94063
0
1
0
0
Chief Scientific Officer
Common Stock
2018-10-09
4
M
0
5500
17.33
A
342241
D
Common Stock
2018-10-09
4
S
0
4400
64.225
D
337841
D
Common Stock
2018-10-09
4
S
0
1100
64.8723
D
336741
D
Employee Stock Option (right to buy)
17.33
2018-10-09
4
M
0
5500
0.00
D
2018-12-04
Common Stock
5500
7000
D
Includes an aggregate of 13,320 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 9, 2018.
Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
Represents weighted average sale price. Actual sale prices ranged from $63.62 to $64.52.
Represents weighted average sale price. Actual sale prices ranged from $64.64 to $65.10.
The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.
/s/ Jason W. Radford, Attorney-in-fact
2018-10-11